Merck & Co., Inc. (MRK)
Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil
Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.
Merck breaks ground on $3B manufacturing plant in Virginia
Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.
Trump strikes deal with Merck to cut IVF drug prices in return for tariff relief
President Donald Trump has unveiled an agreement with Germany's Merck KGaA to lower the cost of its fertility medicines in the United States in exchange for exemptions from threatened tariffs, part of his drive to make in vitro fertilisation (IVF) more affordable. Under the deal, Merck will sell its full range of IVF drugs through Trump's direct-to-consumer platform, TrumpRX, and expand manufacturing in the US.
Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room
Merck & Co., Inc. remains the largest U.S. pharma company in 2025, driven by oncology and Keytruda, despite looming patent expiration risks. Keytruda accounts for over half of MRK's pharmaceutical revenue, making its 2028 patent loss a significant challenge for future growth. MRK management is actively working to offset the Keytruda revenue gap, laying a foundation for post-2028 recovery.
Merck: A Golden Buying Opportunity
Keytruda continues to dominate, driving 50% of revenue, with new approvals and delivery methods strengthening MRK's oncology leadership. The company's long-term outlook is also promising, with a full pipeline of new final-stage drugs, an expanding vaccine portfolio, and breakthroughs in animal health products. Despite patent and regulatory risks, MRK's low valuation, strong balance sheet, and 3.8% dividend yield make it appealing for long-term investors.
Merck (MRK) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Merck (MRK) stood at $84.81, denoting a -1.04% move from the preceding trading day.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Merck (MRK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
